Modality
Vaccine
MOA
BCL-2i
Target
DLL3
Pathway
Amyloid
GAPompe
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
~Nov 2017
→ ~Feb 2019
Phase 3
May 2019
→ Nov 2027
Phase 3Current
NCT06365427
426 pts·GA
2023-02→2027-11·Completed
NCT05287518
1,851 pts·Pompe
2019-05→2026-05·Terminated
2,277 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-111mo awayPh3 Readout· Pompe
2027-11-081.6y awayPh3 Readout· GA
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2026-05-11 · 1mo away
Pompe
Ph3 Readout
2027-11-08 · 1.6y away
GA
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06365427 | Phase 3 | GA | Completed | 426 | EASI-75 |
| NCT05287518 | Phase 3 | Pompe | Terminated | 1851 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |